cancer research technology limited
cancer research technology limited Company Information
Company Number
01626049
Registered Address
2 redman place, london, E20 1JQ
Industry
Research and experimental development on biotechnology
Telephone
02034696300
Next Accounts Due
December 2025
Group Structure
View All
Shareholders
cancer research uk 100%
cancer research technology limited Estimated Valuation
Pomanda estimates the enterprise value of CANCER RESEARCH TECHNOLOGY LIMITED at £168.7m based on a Turnover of £55.2m and 3.06x industry multiple (adjusted for size and gross margin).
cancer research technology limited Estimated Valuation
Pomanda estimates the enterprise value of CANCER RESEARCH TECHNOLOGY LIMITED at £127.9m based on an EBITDA of £10.4m and a 12.27x industry multiple (adjusted for size and gross margin).
cancer research technology limited Estimated Valuation
Pomanda estimates the enterprise value of CANCER RESEARCH TECHNOLOGY LIMITED at £54.6m based on Net Assets of £23.9m and 2.29x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Cancer Research Technology Limited Overview
Cancer Research Technology Limited is a live company located in london, E20 1JQ with a Companies House number of 01626049. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in March 1982, it's largest shareholder is cancer research uk with a 100% stake. Cancer Research Technology Limited is a mature, large sized company, Pomanda has estimated its turnover at £55.2m with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Cancer Research Technology Limited Health Check
Pomanda's financial health check has awarded Cancer Research Technology Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 2 areas for improvement. Company Health Check FAQs
6 Strong
3 Regular
2 Weak
Size
annual sales of £55.2m, make it larger than the average company (£3.3m)
£55.2m - Cancer Research Technology Limited
£3.3m - Industry AVG
Growth
3 year (CAGR) sales growth of -15%, show it is growing at a slower rate (15.2%)
-15% - Cancer Research Technology Limited
15.2% - Industry AVG
Production
with a gross margin of 59.2%, this company has a comparable cost of product (55.8%)
59.2% - Cancer Research Technology Limited
55.8% - Industry AVG
Profitability
an operating margin of 16.9% make it more profitable than the average company (-12.7%)
16.9% - Cancer Research Technology Limited
-12.7% - Industry AVG
Employees
with 281 employees, this is above the industry average (47)
281 - Cancer Research Technology Limited
47 - Industry AVG
Pay Structure
on an average salary of £60.2k, the company has a lower pay structure (£81.1k)
£60.2k - Cancer Research Technology Limited
£81.1k - Industry AVG
Efficiency
resulting in sales per employee of £196.3k, this is more efficient (£126.6k)
£196.3k - Cancer Research Technology Limited
£126.6k - Industry AVG
Debtor Days
it gets paid by customers after 52 days, this is near the average (52 days)
52 days - Cancer Research Technology Limited
52 days - Industry AVG
Creditor Days
its suppliers are paid after 131 days, this is slower than average (58 days)
131 days - Cancer Research Technology Limited
58 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Cancer Research Technology Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 5 weeks, this is less cash available to meet short term requirements (34 weeks)
5 weeks - Cancer Research Technology Limited
34 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 49%, this is a similar level of debt than the average (51.7%)
49% - Cancer Research Technology Limited
51.7% - Industry AVG
CANCER RESEARCH TECHNOLOGY LIMITED financials
Cancer Research Technology Limited's latest turnover from March 2024 is £55.2 million and the company has net assets of £23.9 million. According to their latest financial statements, Cancer Research Technology Limited has 281 employees and maintains cash reserves of £2.4 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 55,157,000 | 76,352,000 | 92,194,000 | 91,355,000 | 106,417,000 | 114,622,000 | 93,898,000 | 82,349,000 | 79,244,000 | 61,861,000 | 61,992,000 | 49,654,000 | 36,702,000 | 32,722,000 | 32,754,617 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost Of Sales | 22,498,000 | 34,728,000 | 45,617,000 | 46,758,000 | 54,642,000 | 59,804,000 | 49,647,000 | 43,623,000 | 43,012,000 | 30,211,000 | 30,652,000 | 26,685,000 | 17,901,000 | 15,735,000 | 16,044,500 |
| Gross Profit | 32,659,000 | 41,624,000 | 46,577,000 | 44,597,000 | 51,775,000 | 54,818,000 | 44,251,000 | 38,726,000 | 36,232,000 | 31,650,000 | 31,340,000 | 22,969,000 | 18,801,000 | 16,987,000 | 16,710,117 |
| Admin Expenses | 23,366,000 | 24,821,000 | 14,607,000 | 12,522,000 | 13,822,000 | 8,399,000 | 8,989,000 | 3,180,000 | 15,173,000 | 11,272,000 | 10,905,000 | 14,647,000 | 14,668,000 | 14,855,000 | 14,210,586 |
| Operating Profit | 9,293,000 | 16,803,000 | 31,970,000 | 32,075,000 | 37,953,000 | 46,419,000 | 35,262,000 | 35,546,000 | 21,059,000 | 20,378,000 | 20,435,000 | 8,322,000 | 4,133,000 | 2,132,000 | 2,499,531 |
| Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39,000 | 20,000 | 10,000 | 35,000 | 18,000 | 18,783 |
| Interest Receivable | 212,000 | 122,000 | 15,000 | 9,000 | 76,000 | 75,000 | 12,000 | 12,000 | 6,000 | 78,000 | 58,000 | 49,000 | 73,000 | 64,000 | 66,807 |
| Pre-Tax Profit | 14,432,000 | -7,892,000 | 38,619,000 | 36,862,000 | 34,065,000 | 51,930,000 | 35,274,000 | 38,057,000 | 21,065,000 | 20,417,000 | 20,473,000 | 8,361,000 | 4,171,000 | 2,178,000 | 2,547,555 |
| Tax | -3,037,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 11,395,000 | -7,892,000 | 38,619,000 | 36,862,000 | 34,065,000 | 51,930,000 | 35,274,000 | 38,057,000 | 21,065,000 | 20,417,000 | 20,473,000 | 8,361,000 | 4,171,000 | 2,178,000 | 2,547,555 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | 11,395,000 | -7,892,000 | 870,000 | 3,588,000 | -4,288,000 | 5,277,000 | 56,000 | 7,880,000 | -3,499,000 | -199,000 | -2,068,000 | 976,000 | 1,997,000 | 1,040,000 | 984,950 |
| Employee Costs | 16,919,000 | 15,319,000 | 10,655,000 | 9,266,000 | 10,347,000 | 8,414,000 | 7,812,000 | 7,483,000 | 7,390,000 | 7,551,000 | 8,287,000 | 7,532,000 | 7,425,000 | 7,356,000 | 6,999,812 |
| Number Of Employees | 281 | 248 | 180 | 166 | 170 | 143 | 130 | 124 | 123 | 124 | 138 | 137 | 131 | 136 | 139 |
| EBITDA* | 10,424,000 | 17,849,000 | 32,817,000 | 32,846,000 | 38,780,000 | 47,114,000 | 35,826,000 | 36,013,000 | 21,456,000 | 20,745,000 | 20,890,000 | 8,769,000 | 4,757,000 | 2,792,000 | 3,102,376 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 3,889,000 | 2,972,000 | 1,881,000 | 2,179,000 | 2,079,000 | 1,714,000 | 1,539,000 | 1,040,000 | 1,003,000 | 1,185,000 | 896,000 | 919,000 | 885,000 | 1,037,000 | 1,273,502 |
| Intangible Assets | 0 | 34,000 | 94,000 | 154,000 | 182,000 | 314,000 | 127,000 | 156,000 | 195,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 415,000 | 376,000 | 7,717,000 | 5,766,000 | 1,186,000 | 5,544,000 | 428,000 | 428,000 | 1,417,000 | 5,435,000 | 5,442,000 | 4,829,000 | 4,910,000 | 4,818,000 | 4,879,531 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 4,304,000 | 3,382,000 | 9,692,000 | 8,099,000 | 3,447,000 | 7,572,000 | 2,094,000 | 1,624,000 | 2,615,000 | 6,620,000 | 6,338,000 | 5,748,000 | 5,795,000 | 5,855,000 | 6,153,033 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 7,927,000 | 4,276,000 | 10,213,000 | 2,717,000 | 4,428,000 | 3,453,000 | 9,723,000 | 3,088,000 | 657,000 | 1,835,000 | 5,570,000 | 2,808,000 | 1,202,000 | 294,000 | 954,574 |
| Group Debtors | 12,859,000 | 38,753,000 | 50,766,000 | 56,171,000 | 63,095,000 | 80,595,000 | 58,782,000 | 33,411,000 | 28,221,000 | 27,631,000 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 19,447,000 | 23,833,000 | 33,499,000 | 38,982,000 | 43,335,000 | 44,651,000 | 44,826,000 | 32,478,000 | 31,095,000 | 30,134,000 | 35,900,000 | 39,950,000 | 10,995,000 | 5,608,000 | 6,038,483 |
| Cash | 2,359,000 | 1,153,000 | 2,593,000 | 2,527,000 | 923,000 | 1,811,000 | 1,639,000 | 1,468,000 | 10,665,000 | 302,000 | 101,000 | 658,000 | 15,500,000 | 15,397,000 | 15,741,304 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 42,592,000 | 68,015,000 | 97,071,000 | 100,397,000 | 111,781,000 | 130,510,000 | 114,970,000 | 70,445,000 | 70,638,000 | 59,902,000 | 41,571,000 | 43,416,000 | 27,697,000 | 21,299,000 | 22,734,361 |
| total assets | 46,896,000 | 71,397,000 | 106,763,000 | 108,496,000 | 115,228,000 | 138,082,000 | 117,064,000 | 72,069,000 | 73,253,000 | 66,522,000 | 47,909,000 | 49,164,000 | 33,492,000 | 27,154,000 | 28,887,394 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 8,129,000 | 1,819,000 | 3,379,000 | 1,892,000 | 658,000 | 894,000 | 1,324,000 | 14,000 | 904,000 | 719,000 | 555,000 | 795,000 | 1,353,000 | 313,000 | 1,956,190 |
| Group/Directors Accounts | 836,000 | 21,698,000 | 37,583,000 | 32,848,000 | 37,930,000 | 46,090,000 | 34,336,000 | 19,093,000 | 23,464,000 | 20,876,000 | 5,258,000 | 10,374,000 | 2,720,000 | 2,771,000 | 3,685,052 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 14,027,000 | 35,371,000 | 45,400,000 | 53,280,000 | 51,593,000 | 56,242,000 | 48,110,000 | 38,064,000 | 41,867,000 | 29,888,000 | 26,309,000 | 19,384,000 | 11,647,000 | 8,189,000 | 8,354,796 |
| total current liabilities | 22,992,000 | 58,888,000 | 86,362,000 | 88,020,000 | 90,181,000 | 103,226,000 | 83,770,000 | 57,171,000 | 66,235,000 | 51,483,000 | 32,122,000 | 30,553,000 | 15,720,000 | 11,273,000 | 13,996,038 |
| loans | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 4,438,000 | 4,438,000 | 5,439,000 | 5,439,000 | 5,439,000 | 5,439,183 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 945,000 | 9,104,000 | 14,625,000 | 18,340,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 86,000 | 255,000 | 10,000 | 147,000 | 253,000 | 303,472 |
| total long term liabilities | 2,000 | 2,000 | 2,000 | 947,000 | 9,106,000 | 14,627,000 | 18,342,000 | 2,000 | 2,000 | 4,524,000 | 4,693,000 | 5,449,000 | 5,586,000 | 5,692,000 | 5,742,655 |
| total liabilities | 22,994,000 | 58,890,000 | 86,364,000 | 88,967,000 | 99,287,000 | 117,853,000 | 102,112,000 | 57,173,000 | 66,237,000 | 56,007,000 | 36,815,000 | 36,002,000 | 21,306,000 | 16,965,000 | 19,738,693 |
| net assets | 23,902,000 | 12,507,000 | 20,399,000 | 19,529,000 | 15,941,000 | 20,229,000 | 14,952,000 | 14,896,000 | 7,016,000 | 10,515,000 | 11,094,000 | 13,162,000 | 12,186,000 | 10,189,000 | 9,148,701 |
| total shareholders funds | 23,902,000 | 12,507,000 | 20,399,000 | 19,529,000 | 15,941,000 | 20,229,000 | 14,952,000 | 14,896,000 | 7,016,000 | 10,515,000 | 11,094,000 | 13,162,000 | 12,186,000 | 10,189,000 | 9,148,701 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 9,293,000 | 16,803,000 | 31,970,000 | 32,075,000 | 37,953,000 | 46,419,000 | 35,262,000 | 35,546,000 | 21,059,000 | 20,378,000 | 20,435,000 | 8,322,000 | 4,133,000 | 2,132,000 | 2,499,531 |
| Depreciation | 1,097,000 | 986,000 | 787,000 | 713,000 | 677,000 | 568,000 | 494,000 | 410,000 | 397,000 | 367,000 | 455,000 | 447,000 | 624,000 | 660,000 | 602,845 |
| Amortisation | 34,000 | 60,000 | 60,000 | 58,000 | 150,000 | 127,000 | 70,000 | 57,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | -3,037,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | -26,629,000 | -27,616,000 | -3,392,000 | -12,988,000 | -17,841,000 | 15,368,000 | 44,354,000 | 9,004,000 | 373,000 | 18,130,000 | -1,288,000 | 30,561,000 | 6,295,000 | -1,091,057 | 6,993,057 |
| Creditors | 6,310,000 | -1,560,000 | 1,487,000 | 1,234,000 | -236,000 | -430,000 | 1,310,000 | -890,000 | 185,000 | 164,000 | -240,000 | -558,000 | 1,040,000 | -1,643,190 | 1,956,190 |
| Accruals and Deferred Income | -21,344,000 | -10,029,000 | -8,825,000 | -6,472,000 | -10,170,000 | 4,417,000 | 28,386,000 | -3,803,000 | 11,979,000 | 3,579,000 | 6,925,000 | 7,737,000 | 3,458,000 | -165,796 | 8,354,796 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -86,000 | -169,000 | 245,000 | -137,000 | -106,000 | -50,472 | 303,472 |
| Cash flow from operations | 18,982,000 | 33,876,000 | 28,871,000 | 40,596,000 | 46,215,000 | 35,733,000 | 21,168,000 | 22,316,000 | 33,161,000 | 6,189,000 | 29,108,000 | -14,750,000 | 2,854,000 | 2,023,599 | 6,723,777 |
| Investing Activities | |||||||||||||||
| capital expenditure | -537,000 | -339,000 | -548,246 | ||||||||||||
| Change in Investments | 39,000 | -7,341,000 | 1,951,000 | 4,580,000 | -4,358,000 | 5,116,000 | 0 | -989,000 | -4,018,000 | -7,000 | 613,000 | -81,000 | 92,000 | -61,531 | 4,879,531 |
| cash flow from investments | -629,000 | -277,469 | -5,427,777 | ||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | -20,862,000 | -15,885,000 | 4,735,000 | -5,082,000 | -8,160,000 | 11,754,000 | 15,243,000 | -4,371,000 | 2,588,000 | 15,618,000 | -5,116,000 | 7,654,000 | -51,000 | -914,052 | 3,685,052 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4,436,000 | 0 | -1,001,000 | 0 | 0 | -183 | 5,439,183 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||||||
| interest | 212,000 | 122,000 | 15,000 | 9,000 | 76,000 | 75,000 | 12,000 | 12,000 | 6,000 | 39,000 | 38,000 | 39,000 | 38,000 | 46,000 | 48,024 |
| cash flow from financing | -20,650,000 | -15,763,000 | 4,750,000 | -5,073,000 | -8,084,000 | 11,829,000 | 15,255,000 | -4,359,000 | -1,842,000 | 15,277,000 | -6,079,000 | 7,693,000 | -13,000 | -867,936 | 17,336,010 |
| cash and cash equivalents | |||||||||||||||
| cash | 1,206,000 | -1,440,000 | 66,000 | 1,604,000 | -888,000 | 172,000 | 171,000 | -9,197,000 | 10,363,000 | 201,000 | -557,000 | -14,842,000 | 103,000 | -344,304 | 15,741,304 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 1,206,000 | -1,440,000 | 66,000 | 1,604,000 | -888,000 | 172,000 | 171,000 | -9,197,000 | 10,363,000 | 201,000 | -557,000 | -14,842,000 | 103,000 | -344,304 | 15,741,304 |
cancer research technology limited Credit Report and Business Information
Cancer Research Technology Limited Competitor Analysis
Perform a competitor analysis for cancer research technology limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other large companies, companies in E20 area or any other competitors across 12 key performance metrics.
cancer research technology limited Ownership
CANCER RESEARCH TECHNOLOGY LIMITED group structure
Cancer Research Technology Limited has 4 subsidiary companies.
Ultimate parent company
1 parent
CANCER RESEARCH TECHNOLOGY LIMITED
01626049
4 subsidiaries
cancer research technology limited directors
Cancer Research Technology Limited currently has 8 directors. The longest serving directors include Mr Peter Chambre (Oct 2011) and Dr Iain Foulkes (Jan 2013).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Peter Chambre | 69 years | Oct 2011 | - | Director | |
| Dr Iain Foulkes | England | 53 years | Jan 2013 | - | Director |
| Dr Deborah Harland | United Kingdom | 64 years | Sep 2015 | - | Director |
| Mr Anthony Hickson | England | 55 years | Aug 2018 | - | Director |
| Mr Parker Moss | England | 49 years | Nov 2019 | - | Director |
| Mr Parker Moss | England | 49 years | Nov 2019 | - | Director |
| Mr Christoph Lengauer | England | 59 years | Apr 2023 | - | Director |
| Ms Anna Jenkins | England | 59 years | Apr 2023 | - | Director |
P&L
March 2024turnover
55.2m
-28%
operating profit
9.3m
-45%
gross margin
59.3%
+8.61%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
23.9m
+0.91%
total assets
46.9m
-0.34%
cash
2.4m
+1.05%
net assets
Total assets minus all liabilities
cancer research technology limited company details
company number
01626049
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
March 1982
age
42
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
March 2024
previous names
cancer research campaign technology limited (October 2002)
carlton medical products limited (April 1988)
accountant
-
auditor
PRICEWATERHOUSECOPERS LLP
address
2 redman place, london, E20 1JQ
Bank
NATIONAL WESTMINSTER BANK PLC
Legal Advisor
-
cancer research technology limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to cancer research technology limited. Currently there are 1 open charges and 0 have been satisfied in the past.
cancer research technology limited Companies House Filings - See Documents
| date | description | view/download |
|---|
